Last reviewed · How we verify
anti-MUC1 CAR T Cells
At a glance
| Generic name | anti-MUC1 CAR T Cells |
|---|---|
| Also known as | anti-MUC1-CAR transduced autologous T cells |
| Sponsor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer (PHASE1, PHASE2)
- CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer (PHASE1, PHASE2)
- Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC (PHASE1, PHASE2)
- CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor (PHASE1, PHASE2)
- CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor (PHASE1, PHASE2)
- Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-MUC1 CAR T Cells CI brief — competitive landscape report
- anti-MUC1 CAR T Cells updates RSS · CI watch RSS
- PersonGen BioTherapeutics (Suzhou) Co., Ltd. portfolio CI